---
title: Centene Corporation (CNC)
layout: default
nav_order: 451
---

# Centene Corporation
{: .fs-9 }

{: .label .label-purple }

Moat: 2/5

{: .label .label-blue }

Management: 3/5

{: .label .label-green }

Catalyst: 3/5

{: .label .label-yellow }

Pessimistic value: $22.9 B

Centene operates in a highly regulated and competitive industry, making sustainable excess returns challenging. While its size offers some advantages, particularly in securing government contracts, I assign a **narrow moat rating of 2 out of 5**.  This is because I believe its competitive advantages are largely tied to scale and government relationships, which, while providing a barrier to entry, are not insurmountable, and are subject to regulatory and political shifts.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=CNC+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/CNC/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning } 
>The moat rating, management rating, catalyst score, and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.


I give Centene's management a **rating of 3 out of 5**. While they have overseen significant growth, their capital allocation decisions and communication could be better. I will explain this in more detail below.

I give Centene's catalyst rating a **3 out of 5**. Centene has growth potential through acquisitions, expansion into new markets, and cost-cutting measures. However, the uncertain regulatory environment tempers this rating.

My **valuation of $22.9 billion** is based on a Discounted Cash Flow (DCF) model and incorporates a degree of pessimism regarding future growth and margins due to the intense competition in the industry and uncertainties surrounding government healthcare programs.

**Business Overview**

Centene is a leading provider of managed care services to government-sponsored healthcare programs, primarily Medicaid.

* **Revenue Distribution:**  Centene's revenue is predominantly (over 90%) derived from government-sponsored health insurance programs, namely Medicaid, Medicare, and related programs. A smaller portion comes from commercial and international markets. This heavy reliance on government funding presents both opportunities and challenges, as the company is exposed to changes in policy and budgetary constraints. From Q3 2023 Earnings call: *"Our 2024 guidance reflects approximately $2 billion of gross profit growth, led by Medicaid and Medicare growth."*
* **Industry Trends:** The managed care industry is consolidating, with larger players gaining market share. This creates opportunities for scale but also intensifies competition. The industry is also subject to increasing regulatory scrutiny and evolving customer needs. From Q3 2023 Earnings call: *"While the pace of rate setting varies from state to state, overall rate setting activity has been constructive."*
* **Margins:** Centene's operating margins are low and volatile. This is a direct consequence of the highly regulated and cost-competitive nature of the industry.  The company attempts to make up for lower margins with higher volumes. From Q3 2023 Earnings call: *"We are raising the midpoint of our adjusted diluted EPS guidance range for 2023 to $6.65, which represents full year growth of more than 10% on a business-as-usual basis."*
* **Competitive Landscape:**  Centene faces intense competition from other large managed care companies, including UnitedHealth Group, Molina Healthcare, and Anthem. What differentiates Centene is its focus on government-sponsored healthcare programs, where it has built a leading position.
* **Differentiation:**  Centene's primary competitive advantage comes from scale and established relationships with government agencies.  The company's size and expertise in managing complex government programs create barriers to entry for new competitors.

**Management Assessment**

* **History & Experience:** Centene's management team, led by CEO Sarah London, has overseen substantial growth in recent years. However, the company has also faced regulatory challenges and integration issues related to acquisitions. 
* **Compensation:** Executive compensation appears to be largely tied to growth and financial metrics, potentially incentivizing short-term decision-making at the expense of long-term value creation. From 2023 Proxy Statement *"The Committee reviews and approves our Named Executive Officers' compensation annually."* 
* **Insider Ownership:**  Insider ownership is relatively low, suggesting a potential misalignment of interests between management and shareholders.  This needs further scrutiny. 
* **Communication:**  While Centene does provide regular updates to investors, it could be more transparent about the long-term drivers of value creation. 
* **Capital Allocation:** Management has engaged in a string of acquisitions, but not all of them have been successful in creating value. This raises concerns about the company's capital allocation discipline. From 2019 10K *"The Company completed the acquisition of Magellan Health, Inc on January 4, 2022."*

**Valuation**

I used a **two-stage DCF model** to value Centene.

**Assumptions**

{: .important }

**Stage 1 (Years 1-5):**

* **Revenue Growth:** 5% annually (Conservative, reflects industry slowdown and potential for regulatory changes). From Q3 2023 Earnings call: *"Medicaid redeterminations are progressing largely as expected and as we anticipated."*
* **Operating Margin:**  Gradually increasing from 2.8% to 3.2% (Reflects management's focus on cost improvements).
* **Reinvestment Rate:**  65% (Consistent with historical reinvestment rates, reflecting ongoing growth needs). From Q3 2023 Earnings call: *"During the third quarter, we invested $754 million in our core businesses."* 
* **Cost of Equity:** 10.4% (Derived using the Capital Asset Pricing Model (CAPM), assuming a beta of 1.2, a risk-free rate of 4%, a market risk premium of 5.5%, and a country risk premium of 1%). From Q2 2023 Earnings call: *"We are seeing a substantial increase in interest expense year-over-year due to higher interest rates impacting both operating and non-operating expenses."*
* **Cost of Debt:** 5.2% (Reflects current market yields for debt with a similar rating and maturity). From Q2 2023 Earnings call: *"Given elevated interest rates in the current environment, we remain focused on managing our interest expense."* 
* **Tax Rate:** 21% (The company's current marginal statutory tax rate).

{: .important }

**Stage 2 (Perpetuity):**

* **Growth Rate:** 3% annually (Conservative, reflects long-term economic growth expectations).
* **Return on Invested Capital (ROIC):** 10% (Slightly above the cost of capital, reflecting sustainable long-term value creation). From Q2 2023 Earnings call: *"Our long-term view of the managed care industry, which we now call Medicare-Medicaid Duals, remains extremely positive."*

{: .important }

**Other Assumptions:**

* **Weighted Average Cost of Capital (WACC):** 7.6% (Derived using the target capital structure).
* **Terminal Value:** Calculated using the perpetuity growth model.

**Calculations**

{: .note }

I projected Centene's free cash flow (FCF) for the next five years using the above assumptions, discounted the FCF back to its present value using the WACC, and added the present value of the terminal value.  I then subtracted the value of debt and other non-equity claims (such as minority interests and employee stock options), and divided by the number of shares outstanding to arrive at the value per share. Due to limited space, the detailed calculations are not displayed here. However, an example of how these calculations are typically laid out in a DCF valuation can be seen in Chapter 3 of the *Little Book of Valuation*.

**Sensitivity Analysis & Scenario Planning**

I performed sensitivity analysis on key assumptions such as revenue growth and margins, and found that the valuation is most sensitive to changes in the long-term growth rate.

I also developed alternative scenarios (optimistic, pessimistic, and base case) to account for uncertainty related to Medicaid expansion, the Affordable Care Act (ACA), and potential for future acquisitions. This process of creating scenarios can be seen in Chapter 13 of *The Little Book of Valuation*.

**Conclusion**

While Centene has considerable growth potential in a large market, achieving and sustaining profitable growth is a key challenge. The company faces intense competition and ongoing regulatory headwinds that could compress margins and limit pricing power.  Therefore, a cautious, value-driven approach is warranted when investing in Centene. The margin of safety built into the valuation mitigates some of these concerns.  Centene's management needs to execute effectively and demonstrate consistent value creation to justify a higher valuation. The company should prioritize improving margins, reinvesting for growth wisely, and improving communication with investors.